Curileum Discovery

Executive Summary

Curileum Discovery is a UK-based preclinical biotechnology company founded in 2018, dedicated to developing first-in-class small molecule therapies that restore gastrointestinal tissue health. The company addresses early disease intervention to prevent colorectal cancer and treat inflammatory bowel disease (IBD). Its lead asset, ULI262, is an oral drug designed to redirect precancerous cells toward normal tissue, offering a novel approach to halt disease progression. With a strong scientific foundation from Cambridge, Curileum is positioned to enter a significant market opportunity in GI oncology and chronic inflammation. However, as a preclinical company with no disclosed funding or partnerships, execution risk remains high. The compelling science and unmet medical need support a conviction score of 60, reflecting the potential upside balanced by early-stage uncertainty.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for ULI26270% success
• Q4 2026Series A Funding or Partnership Announcement50% success
• Q1 2027IND/CTA Filing for ULI26240% success